HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders.

AbstractBACKGROUND:
TGFBR2 mutations were recognized recently among patients with a Marfan-like phenotype. The associated clinical and prognostic spectra remain unclear.
METHODS AND RESULTS:
Clinical features and outcomes of 71 patients with a TGFBR2 mutation (TGFBR2 group) were compared with 50 age- and sex-matched unaffected family members (control subjects) and 243 patients harboring FBN1 mutations (FBN1 group). Aortic dilatation was present in a similar proportion of patients in both the TGFBR2 and FBN1 groups (78% versus 79%, respectively) but was highly variable. The incidence and average age for thoracic aortic surgery (31% versus 27% and 35+/-16 versus 39+/-13 years, respectively) and aortic dissection (14% versus 10% and 38+/-12 versus 39+/-9 years) were also similar in the 2 groups. Mitral valve involvement (myxomatous, prolapse, mitral regurgitation) was less frequent in the TGFBR2 than in the FBN1 group (all P<0.05). Aortic dilatation, dissection, or sudden death was the index event leading to genetic diagnosis in 65% of families with TGFBR2 mutations, versus 32% with FBN1 mutations (P=0.002). The rate of death was greater in TGFBR2 families before diagnosis but similar once the disease had been recognized. Most pregnancies were uneventful (without death or aortic dissection) in both TGFBR2 and FBN1 families (38 of 39 versus 213 of 217; P=1). Seven patients (10%) with a TGFBR2 mutation fulfilled international criteria for Marfan syndrome, 3 of whom presented with features specific for Loeys-Dietz syndrome.
CONCLUSIONS:
Clinical outcomes appear similar between treated patients with TGFBR2 mutations and individuals with FBN1 mutations. Prognosis depends on clinical disease expression and treatment rather than simply the presence of a TGFBR2 gene mutation.
AuthorsDavid Attias, Chantal Stheneur, Carine Roy, Gwenaëlle Collod-Béroud, Delphine Detaint, Laurence Faivre, Marie-Ange Delrue, Laurence Cohen, Christine Francannet, Christophe Béroud, Mireille Claustres, Franck Iserin, Philippe Khau Van Kien, Didier Lacombe, Martine Le Merrer, Stanislas Lyonnet, Sylvie Odent, Henri Plauchu, Marlène Rio, Annick Rossi, Daniel Sidi, Philippe Gabriel Steg, Philippe Ravaud, Catherine Boileau, Guillaume Jondeau
JournalCirculation (Circulation) Vol. 120 Issue 25 Pg. 2541-9 (Dec 22 2009) ISSN: 1524-4539 [Electronic] United States
PMID19996017 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • FBN1 protein, human
  • Fibrillin-1
  • Fibrillins
  • Microfilament Proteins
  • Receptors, Transforming Growth Factor beta
  • Protein Serine-Threonine Kinases
  • Receptor, Transforming Growth Factor-beta Type II
Topics
  • Adolescent
  • Adult
  • Aortic Dissection (epidemiology, genetics)
  • Aortic Aneurysm (epidemiology, genetics)
  • Case-Control Studies
  • Child
  • Cohort Studies
  • Female
  • Fibrillin-1
  • Fibrillins
  • Humans
  • Incidence
  • Kaplan-Meier Estimate
  • Male
  • Marfan Syndrome (diagnosis, genetics, mortality)
  • Microfilament Proteins (genetics)
  • Middle Aged
  • Mitral Valve Insufficiency (epidemiology, genetics)
  • Mitral Valve Prolapse (epidemiology, genetics)
  • Mutation (genetics)
  • Phenotype
  • Pregnancy
  • Prognosis
  • Protein Serine-Threonine Kinases (genetics)
  • Receptor, Transforming Growth Factor-beta Type II
  • Receptors, Transforming Growth Factor beta (genetics)
  • Survival Rate
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: